NEXUM BIO

Science. Strategy. Expansion.

Commercial entry into Latin America for advanced diagnostics and therapy technologies

We help precision medicine and advanced diagnostics technology manufacturers reach Latin American clinical markets.

Your technology is ready. Your science is proven. What remains is the market, and this is our work.

There is a gap between advanced diagnostics and therapy technologies, and the Latin American clinical market they could reach. The innovation exists. The route to the clinic does not.

Nexum Bio closes that gap.

We act as your regional commercial team before you have one:

Opening doors to the right stakeholders.
Selecting partners with sector judgement.
Anchoring execution through to a quantified pipeline.

Service model

We open doors. You enter markets.

We don't sell market studies and distributor lists that you could buy anywhere. We deliver access, the right partner and a pipeline you can measure.

Market Entry Assessment

2-3 months · fixed scope

We don't research the market from a desk. We go into it. We sit in real meetings with the people who decide and give you a first-hand read on whether the opportunity is real and who to partner with.

Partner Selection & Onboarding

3-6 months · retainer

We lead negotiations with pre-selected distributors, structure commercial contracts with local counsel, define operating KPIs and reporting, and run a joint commercial kickoff across the first 10-15 target accounts.

Fractional Commercial Management

12-24 months · retainer + performance

An outsourced regional director. Monthly reporting to European management, hands-on distributor management, representation at regional congresses, and a structure linked to results.

Areas of expertise

Where innovation meets the clinic. Our three areas of focus.

We operate at the intersection of scientific innovation and clinical application. We connect the technologies at the leading edge of diagnostics and therapy with the markets ready to adopt them.

— Molecular oncology diagnostics

NGS tumour profiling
Liquid biopsy for ctDNA and MRD
Companion diagnostics
Advanced molecular pathology

— Clinical genomics

Pharmacogenomics for oncology and psychiatry
Hereditary onco-genetics
Reproductive genetics
Rare disease diagnostics

— Advanced therapies

ATMP clinical trial site identification and support
Regulatory and market access advisory for cell and gene therapy programmes
Legal and compliance guidance for advanced therapy entry
Strategic consulting for institutions building advanced therapy capabilities

Strategic advisory

Why Nexum Bio

What manufacturers actually buy

Real access, fast

The first relevant meetings, with the people who hold real purchasing and clinical decision power, happen within the first 30 days. Not introductions. Meetings with the people who decide.

Lower partner risk

The wrong distributor can lock a market for three to five years of exclusivity. We evaluate candidates with objective criteria and prior sector experience, not a list compiled from LinkedIn.

Execution, not slideware

We set targets, close distributors, join commercial visits and report a quantified pipeline month by month. Recommendations alone carry little value.

Senior, on the ground

More than fifteen years in scientific reagent and instrumentation distribution, fluent in the language business development teams use. You walk into the market with a partner who already belongs there.

How we work

From assessment to managed market

Assess

A fixed-scope Market Entry Assessment maps the market and shortlists partners. Low risk, clear deliverables.

Validate

Value is proven within the first 60 days. Both sides decide whether the fit is right before any long commitment.

Scale

The relationship grows into partner onboarding and fractional commercial management as the opportunity matures.

Who we are

Fifteen years of sector experience, applied to your market entry.

We have launched products in hospital environments, navigated regulatory frameworks, built commercial teams and closed distribution agreements across the sector. When we open a door for you, we know what is on the other side.